Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM230G is a type of long intergenic non-coding RNA (lincRNA) gene located on human chromosome 22 as part of the FAM230 family, which contains several other lincRNAs formed by duplication events in segmental regions of chromosome 22 known as LCR22s[1][5][3]. FAM230G is not a protein-coding gene, receptor, enzyme, transporter, or transcription factor, and currently lacks evidence of a direct role in disease, therapeutic targeting, or as a drug-interacting target. Its expression has been observed mainly in the testes, and like other FAM230 family members, it may play structural or regulatory roles in chromosome organization and RNA metabolism during development, particularly in regions prone to chromosomal rearrangements such as 22q11.2[1]. No drugs are known to target FAM230G, and no mechanisms of action or biomarker relevance have been established. Since this entry refers to a non-coding RNA locus with unclear function and no direct evidence supporting its use as a therapeutic target, it is not considered a typical therapeutic target. Its gene annotation (AC007731.1) is an older genomic identifier for the locus and is commonly used as a synonym.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 230 member G (FAM230G).